WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • WJAHR: DECEMBER ISSUE PUBLISHED

    DECEMBER 2024 Issue has been successfully launched on DECEMBER 2024.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR December 2024 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

Best Article Awards

World Journal of Advance Healthcare Research (WJAHR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

ROLE OF NARROW-BAND UVB IN THE TREATMENT OF GENERALIZED VITILIGO IN MOSUL

Abedrazak Mohammad Ibrahim*

ABSTRACT

Background: Vitiligo is a stigmatizing disorder that can cause cosmetic disfigurement and cause severe psychological issues in daily life. About 0.5% of the world's population experiences it, and males experience it just as frequently as girls. The UV radiation's well-established immune-modulatory effects may account for the stability of both local and systemic aberrant immunological responses. Aim of the study: Toohedthsfeshhassha htth shadta BVrBamtassha sfhesehtsadtarmsmomeda.aPatients and Methods: This prospective case-series study includes 50 patients with generalized Vitiligo who attending the Dermatology Unit at Al-Salam Teaching Hospital. After examination, the objective of the study was discussed with the patients and verbal consent was taken for the participation in the study. The patients were referred to the researcher private clinic for the treatment. Therapy was administered three times per week on nonconsecutive days and a standard initial dose of 280 mJ/cm2 was started in all patients and the study period extended for 12 months; from June 2021 to May 2022. Results: The mean age is 19.4± 3.2 years. Seventeen patients are males and thirty three are females with a Female: male ratio is 1.94:1. Most of males and female are below the age of 20 years; 29.4% and 35.3% of males are at the age group (?10 years) and (11-20 years) respectively. The females at the (?10 years) age group are 21.2% and at the (11-20 years) age group are 51.5%. The mean duration is 9.4±1.1 years with a range of 0.5-17 years. 7(14.0%) of the patients have excellent response, 19(38.0%) good response, 14(28.0%) moderate response, while 10(20.0%) have poor response. Most of the patients 45 (90.0%) did not report any side effect. The recorded side effects are mild erythema is 2(4.0%), pruritis 1(2.0%), burning pain 1(2.0%), and xerosis 1(2.0%). Conclusion: Conclusion: Many patients had re-pigmentation quickly as a result of this therapy regimen. This data supports earlier studies by showing that narrow-band UVB is an effective and well-tolerated treatment for vitiligo.

[Full Text Article] [Download Certificate]